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g.2013.0Abstract In end stage renal disease, inﬂammation is considered a critical regulator of atheroscle-
rotic plaque formation and progression, to which many dialysis and non-dialysis-related factors
may contribute. Since circulating inﬂammatory cytokine levels vary inter-individually, one may
speculate that genetic factors, such as polymorphisms in genes encoding them, may be involved
in determining the individual inﬂammatory reaction in response to a given insult. The present work
aimed to study interleukin-1B (-511C/T), and interleukin-6 (-174G/C) gene polymorphisms and
their possible association with atherosclerosis in Egyptian patients with end stage renal disease
on maintenance haemodialysis. The present study was conducted on 100 Egyptian subjects, the con-
trol group (n= 30) and the patient group (n= 70) with end stage renal disease on maintenance
haemodialysis which were further subdivided into two subgroups with (n= 33) and without athero-
sclerosis (n= 37) as evidenced by CIMT, ECG ischaemic changes, cerebrovascular insufﬁciency
(CVI), and peripheral vascular insufﬁciency (PVI). All studied subjects were subjected to detailed
history taking, routine laboratory investigations and molecular studies including detection of IL-
1B (-511C/T) and IL-6 (-174G/C) gene polymorphisms using the Polymerase chain reaction/
Restriction fragment length polymorphism (PCR/RFLP) technique. The genotype distribution
and allele frequency of IL-1B (-511C/T) and IL-6 (-174G/C) showed no statistical signiﬁcant4037292.
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268 M.H. Kandil et al.difference among the studied groups. To conclude the development of atherosclerosis among Egyp-
tian patients on maintenance haemodialysis cannot be attributed to these two gene polymorphisms.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.Figure 1 Agarose gel electrophoresis of PCR products digested
with AvaI restriction enzyme. Lane 4: 50 bp DNA Ladder (50–
1000 bp). Lane 1, 3: TT homozygote alleles (bands at 114 bp and
190 bp). Lane 2, 6, 7, 8, 9: CT heterozygote alleles (bands at
114 bp, 190 bp, and 304 bp). Lane 10: CC homozygote alleles
(band at 304 bp).1. Introduction
In end stage renal disease (ESRD), endothelial dysfunction
and atherosclerosis are almost universal [1]. Patients with
ESRD especially those treated with haemodialysis (HD) are
at increased risk for both morbidity and mortality from car-
diovascular diseases [2]. In HD patients, the high prevalence
of traditional cardiovascular risk factors contributes to the
excessive risk of cardiovascular diseases. Nevertheless, studies
focused on non-traditional risk factors, such as oxidative stress
and inﬂammation in ESRD [3,4].
Inﬂammation is considered as a critical regulator of athero-
sclerotic plaque formation and progression leading to the fatal
clinical endpoints; myocardial infarction, stroke, gangrene and
sudden cardiac death [5]. Many uraemic patients show serolog-
ical evidence of an activated inﬂammatory response, as indi-
cated by increased circulating levels of non-speciﬁc markers
of inﬂammation such as C-reactive protein (CRP) and pro-
inﬂammatory cytokines such as IL-1 and IL-6 [4]. It was found
that IL-1B plays an important role in the pathogenesis of ath-
erosclerosis [6–8]. In addition interleukin-6 (IL-6) is associated
with endothelial damage and initiation of atherosclerotic
events [9]. Its expression and secretion are regulated by IL-1
and TNF-a, which are highly induced in the atherosclerotic
plaque [10].
In ESRD, it seems conceivable that both dialysis and non-
dialysis-related factors may contribute to a state of chronic
inﬂammation [11]. Since circulating cytokine levels vary con-
siderably inter-individually, one may speculate that genetic
factors, such as polymorphisms in genes encoding them, may
be involved in determining the individual inﬂammatory reac-
tion in response to a given insult [12]. Many epidemiological
studies have investigated the association between atherosclero-
sis and inﬂammatory cytokine gene polymorphisms [13,14].
One important single nucleotide polymorphism (SNP) is IL-
1B -511(C > T) in which the cytosine residue is substituted
by thymine at position -511 at the promoter region of IL-1B
gene [15]. In addition, many SNPs were determined in the 50
ﬂanking region of the IL-6 gene. One of these SNPs is -
174G/C in which the guanine residue is substituted by cytosine
at position -174 [16].
2. Aim of this work
The present work was designed to study interleukin-1 beta
(-511C/T), and interleukin-6 (-174G/C) gene polymorphisms
and their possible association with atherosclerosis in Egyptian
patients with end stage renal disease on maintenance
haemodialysis.
3. Subjects and methods
Subjects: After the approval of the Ethics Committee of the
Medical Research Institute, informed consents were taken
from all subjects who participated in the study.The present study included one hundred subjects, divided
into two main groups; Control group: which included 30 appar-
ently healthy volunteers of comparable age and socioeconomic
status to the patient group; 13 males (43.3%) and 17 females
(56.7%), their mean age was 43.2 ± 10.1 years and Patient
group: which included seventy patients with end stage renal
disease on maintenance haemodialysis for more than
6 months, (35 males (50%) and 35 females (50%)), their mean
age was 47.8 ± 11.7 years and their duration of dialysis ranged
from 12 months to 192 months with median 47.5 months.
They were selected from the Nephrology Unit of Medical
Research Institute, Alexandria University. The dialysis ses-
sions for these patients were three times weekly and the dura-
tion range of each session was four hours. A standard dialysis
prescription using a cuprophane hollow ﬁbres dialyser was
adopted. The patients were further subdivided according to
the presence of atherosclerosis as evidenced by carotid intima
media thickness measurement (CIMT), 12 leads standard elec-
trocardiography (ECG), cerebrovascular insufﬁciency (CVI),
and peripheral vascular insufﬁciency (PVI) into two sub-
groups: Group A included 33 patients (18 (54.5%) males and
15 (45.5%) females) without atherosclerosis; their mean age
was 43.6 ± 11.9 years and group B included 37 patients (17
(45.9%) males & 20 (54.1%) females) with atherosclerosis,
their mean age was 51.5 ± 10.4 years. Both groups were ex-
posed to comparable haemodialysis conditions.
Both groups were exposed to detailed history with special
emphasis on age and duration of dialysis and thorough phys-
ical examination with special stress on the measurement of
arterial blood pressure, and body mass index. Following an
overnight fasting period and immediately before dialysis ses-
sion, 10 mL whole venous blood were withdrawn from each
Figure 2 Agarose gel electrophoresis of PCR products digested
with N1aIII restriction enzyme. Lane 1: 50 bp DNA Ladder (50–
1000 bp). Lane 2: GC heterozygote alleles (bands at 54 bp, 111 bp,
122 bp and 233 bp). Lane 3, 4, 5, 6, 7, 9: GG homozygote alleles
(bands at 54 bp and 233 bp). Lane 8: CC homozygote alleles
(bands at 54 bp, 111 bp and 122 bp).
Table 1 Some clinical data of different studied groups.
X SD Range median
Control group
(n= 30)
G
(
Age (years) X 43.2 4
±SD 10.1 1
Sex Females 17 (56.7%) 1
Males 13 (43.3%) 1
Duration of dialysis (months) Range – 2
Median – 4
Weight (kg) X 63.1 6
±SD 6.9 1
Height (m) X 164 1
±SD 0.88 0
BMI (kg/m2) X 23.4 2
±SD 0.4 3
SBP (mmHg) X 114 1
±SD 6.7 1
DBP (mmHg) X 74.8 7
±SD 4.9 9
MBP (mmHg) X 87.9 9
±SD 4.9 1
CIMT (mm) Range 0.1–0.5 0
Median 0.3 0
Group A: Patients with ESRD on maintenance haemodialysis without at
Group B: Patients with ESRD on maintenance haemodialysis with ather
n: Number of subjects.
P1: Statistical signiﬁcance between the control group and group A.
P2: Statistical signiﬁcance between the control group and group B.
P3: Statistical signiﬁcance between the control group and total patient gr
P4: Statistical signiﬁcance between group A and group B.
F = Female , M=Male.
BMI = Body mass index; SBP = Systolic blood pressure; DBP = Diasto
intima media thickness.
* Signiﬁcant at P< 0.05.
** Highly signiﬁcant at P< 0.01.
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being connected to the dialysis machine.
One mL of whole blood was mixed with 50 uL of 3.8% Eth-
ylene Diamine Tetraacetic Acid (EDTA) for molecular studies
and the rest 9 mL whole blood was left to clot and the obtained
serum was used for determination of the concentrations of the
traditional analytes for all subjects using an automatic auto
analyser (Olympus, Germany) including fasting serum glucose,
creatinine, triglycerides, cholesterol (total, high and low density
lipoprotein fractions), albumin and C-reactive protein levels.
Molecular studies for detection of IL-1B (-511C/T) and IL-6
(-174G/C) gene polymorphisms were done to all subjects using
the Polymerase chain reaction/Restriction fragment length
polymorphism (PCR/RFLP) technique and included DNA
extraction from peripheral blood leucocytes using Gene
JET Genomic DNA puriﬁcation Kit (Fermentas – Thermo,
USA). Purity of extracted genomic DNA was detected by aga-
rose gel electrophoresis of the yield on 1% agarose gel. In addi-
tion, the genomic DNA concentration was measured on a
nanodrop 1000 spectrophotometer (Thermo scientiﬁc-USA)
at 260 and 280 nm. The mean concentration of the puriﬁed
genomic DNA was 20.56 ng/uL. After extraction, IL-1geneP-value
roup A
n= 33)
Group B
(n= 37)
Total patients
(n= 70)
3.6 51.5 47.8 P2 = 0.002
**
P4 = 0.003
**1.9 10.4 11.7
5 (45.5%) 20 (54.1%) 35 (50%) 0.641
8 (54.5%) 17 (45.9%) 35 (50%)
4–192 12–180 12–192 0.829
8 42 47.5
2.9 67.3 65.2 0.146
0.2 12.6 11.7
60.7 161 160.9 0.301
.71 0.17 0.91
4.4 25.8 25.2 P2 = 0.003
**
P3 = 0.016
*.9 3.9 3.9
21.5 121.9 121.7 P1 = 0.047
*
P2 = 0.032
*
P3 = 0.018
*
6.9 16.5 16.6
8.8 78.6 78.7 P3 = 0.029
*
.3 8.9 8.9
3 93.1 93 P1 = 0.044
*
P2 = 0.037
*
P3 = 0.019
*
1.5 11.1 11.3
.3–0.7 0.8–1.4 0.3–1.4 P1 = 0.000
**
P2 = 0.000
**
P3 = 0.000
**
P4 = 0.000
**
.5 1.0 0.8
herosclerosis.
osclerosis.
oup.
lic blood pressure; MBP=Mean blood pressure; CIMT= Carotid
270 M.H. Kandil et al.promoter region was ampliﬁed using primers [17](1) [F5-TGG
CAT TGA TCT GGT TCA TC-3 (forward), R5-GTT TAG
GAA TCT TCC CAC TT-3 (reverse)] and IL-6 1gene promoterTable 3 Genotype frequencies of IL-1B -511(C > T) polymorphism
Genotype n Control group (n= 30) Group
%
CC n 12 12
% 40 36.4
CT n 15 20
% 50 60.6
TT n 3 1
% 10 3
Chi-square p-value 4.662
0.188
Group A: Patients with ESRD on maintenance haemodialysis without a
Group B: Patients with ESRD on maintenance haemodialysis with ather
n: Number of subjects.
P< 0.05 is signiﬁcant.
Table 2 Some biochemical data of different studied groups.
X SD Range median
Control group (n= 30) Group A (n=
FSG (mg/dl) X 81.5 106.2
±SD 8.9 36.2
Creatinine (mg/dl) X 0.8 10.3
±SD 0.2 2.7
Albumin (g/dl) XX 4.2 3.8
±SD 0.4 0.4
CRP (mg/L) Range 1.0–4.7 1.0–22
Median 2.5 2.8
TG (mg/dl) Range 68–149 71–389
Median 106 140
TC (mg/dl) Range 120–190 115–238
Median 158 163
HDL-C (mg/dl) Range 41–67 19–53
Median 55 30
LDL-C (mg/dl) Range 54–96 57–157
Median 82 86.4
Group A: Patients with ESRD on maintenance haemodialysis without a
Group B: Patients with ESRD on maintenance haemodialysis with ather
n: Number of subjects.
P1: Statistical signiﬁcance between the control group and group A.
P2: Statistical signiﬁcance between the control group and group B.
P3: Statistical signiﬁcance between the control group and total patient gr
P4: Statistical signiﬁcance between group A and group B.
FSG= Fasting serum glucose CRP= C-reactive protein; TG= Trigly
fractions; LDL-C = Low density lipoprotein fractions
* Signiﬁcant at P< 0.05.
** Highly Signiﬁcant at P< 0.01.region was also ampliﬁed using primer [18](2) [F5-TTG TCA
AGA CAT GCC AAA GTG-3 (forward), R5-TCA GAC
ATC TCC AGT CCT ATA-3 (reverse)]. Ampliﬁcations wereamong the studied groups.
A (n= 33) Group B (n= 37) Total patients (n= 70)
10 22
27 31.4
21 41
56.8 58.6
6 7
16.2 10
therosclerosis.
osclerosis.
P-value
33) Group B (n= 37) Total patients (n= 70)
154 131.5 P2 = 0.000
**
P3 = 0.000
**
P4 = 0.000
**
79.8 67.2
9.2 9.7 P1 = 0.000
**
P2 = 0.000
**
P3 = 0.000
**
2.8 2.8
3.8 3.8 P1 = 0.000
**
P2 = 0.000
**
P3 = 0.000
**
0.3 0.4
1.1–23 1.0–23 P1 = 0.009
**
P2 = 0.000
**
P3 = 0.000
**
4.2 3.5
60–399 60–399 P1 = 0.017
*
P2 = 0.000
**
P3 = 0.000
**
P4 = 0.020
*
183 161.5
98–311 98–311 P2 = 0.004
*
P3 = 0.022
*
P4 = 0.040
*
169 168
16–53 16–53 P1 = 0.000
**
P2 = 0.000
**
P3 = 0.000
**
32 31
43–194 43–194 P1 = 0.002
**
P2 = 0.000
**
P3 = 0.000
**
103 99
therosclerosis.
osclerosis.
oup.
cerides TC = Total cholesterol; HDL-C = High density lipoprotein
Table 4 IL-1B -511(C > T) allele frequency among the studied groups.
Allele n Control group (n= 30) Group A (n= 33) Group B (n= 37) Total patients (n= 70)
%
C n 39 44 41 85
% 65 66.7 55.4 60.7
T n 21 22 33 55
% 35 33.3 44.6 39.3
Chi-square
P-value
2.21
0.332
Group A: Patients with ESRD on maintenance haemodialysis without atherosclerosis.
Group B: Patients with ESRD on maintenance haemodialysis with atherosclerosis.
n: Number of subjects.
P< 0.05 is signiﬁcant.
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3 min) · 1; (95 C, 30 s, 55 C, 30 s, 72 C, 60 s) · 37; (72 C,
10 min) · 1, using DreamTaq Green PCR Master Mix (Fer-
mentas – Thermo, USA). Restriction digestion of PCR prod-
ucts was done using FastDigestAvaI enzyme (Fermentas –
Thermo, USA) for IL-1B (-511C/T). The digestion products
were subjected to 2.5% agarose gel electrophoresis and showed
that allele C which did not contain the AvaI restriction enzyme
site remained undigested as 304 bp fragments, whereas allele T
yields 190 bp and 114 bp fragments (Fig. 1). As regards the
detection of IL-6 (-174G/C) gene polymorphism, FastDigest
N1a III restriction enzyme (Fermentas – Thermo, USA) was
used. The digestion products were subjected to 2.0% agarose
gel electrophoresis and showed that allele G which did not con-
tain the N1a III restriction enzyme site was digested to 233 bp
and 54 bp fragments, whereas allele C yielded 122 bp, and
111 bp together with the 54 bp fragment (Fig. 2).
4. Statistical analysis [19]
Statistical assessment was carried out with Statistical Package
for Social Sciences (SPSS) version 17.0 for Windows statistical
software [20]. Quantitative variables were tested for normality
using Kolmogorov–Smirnov test. Data revealed normal distri-
bution was represented as mean ± standard deviation, and the
data revealed deviation from normal distribution was repre-
sented as median and range.
Analysis of variance (ANOVA) or F-test is used for com-
parison between more than two means when the data are nor-
mally distributed. Kruskal–Wallis was used for testing equality
of population medians among groups. Mann–Whitney (U)
and Chi-square (X2) tests were used. Allele and genotype fre-
quencies among cases and controls were compared with
Hardy–Weinberg predictions using X2 analysis. P Value of less
than 0.05 was considered statistically signiﬁcant.5. Results
The results of some clinical and biochemical data of the differ-
ent studied groups are included in Tables 1 and 2. It could be
noticed that there was no signiﬁcant difference between any of
the groups regarding sex and there were no signiﬁcant differ-
ences between group A and group B regarding duration of
dialysis. However age and CIMT, FSG, TG, TC were signiﬁ-cantly higher in group B than group A. As regards CRP, it
was signiﬁcantly higher in total patient group than the control
group (p= 0.000*).
In group B, 32 (86.5%) patients had ECG changes of
ischaemic heart diseases, 5 (13.5%) patients had cerebrovascu-
lar insufﬁciency, 3 (8.1%) patients had peripheral vascular
insufﬁciency and 11 (29.7%) patients had atherosclerotic pla-
ques. None of the observed genotype frequencies deviated
from the Hardy–Weinberg equilibrium. There was no signiﬁ-
cant difference in IL-1B (-511) genotypes and its allele fre-
quency distributions among the studied groups (X2 = 4.662,
P= 0.188) (Table 3) (X2 = 2.21, P= 0.332) (Table 4),
respectively.
In the present study, no signiﬁcant correlation was found
between IL-1B (-511C > T) variants and the different studied
parameters (Table 5).
Also there was no signiﬁcant difference in IL-6 (-174) geno-
types and its allele frequency distributions among the studied
groups (X2 = 2.689, P= 0.611) (Table 6) (X2 = 2.01,
p= 0.365) (Table 7), respectively.
No signiﬁcant correlation was found between IL-6 (-174G/
C) variants and the different studied parameters (Table 8).
6. Discussion
Chronic kidney disease is at least 3–4 times more frequent in
Africa than in developed countries [21], and in Egypt, the prev-
alence of dialysis patients is presumed to be increasing [22].
Many risk factors and metabolic alterations observed in the
uraemic milieu may contribute to the excessive risk of athero-
sclerosis in dialysis patients [23]. Many epidemiological studies
have investigated the association between atherosclerosis and
inﬂammatory cytokine gene polymorphisms. However, it re-
mains to be seen whether or not the genetic factors for these
inﬂammation-related mediators underlie atherogenesis [24].
We studied the possible association between interleukin-1 beta
(-511C/T), and interleukin-6 (-174G/C) gene polymorphisms
and atherosclerosis in end stage renal disease Egyptian patients
on maintenance haemodialysis.
In the present study no signiﬁcant difference was observed
in the genotype distribution of IL-1B (-511) among the studied
groups. In addition, no signiﬁcant difference was observed in
the frequency of the IL-1B (-511) alleles among the studied
groups. These were in agreement with Arman et al. [15] who
did not ﬁnd any association in either allele frequency or
Table 5 Comparison of the measured variables between
different genotypes of IL-1B -511(C > T) polymorphism.
Variables Genotypes F Sig.
Weight CC 0.997 0.373
CT
TT
Height CC 1.169 0.315
CT
TT
BMI CC 0.848 0.431
CT
TT
SBP CC 0.827 0.440
CT
TT
DBP CC 0.177 0.838
CT
TT
MBP CC 0.450 0.639
CT
TT
CIMT CC 2.071 0.132
CT
TT
FSG CC 0.622 0.539
CT
TT
Creatinine CC 0.139 0.870
CT
TT
Albumin CC 0.339 0.713
CT
TT
CRP CC 1.237 0.295
CT
TT
TG CC .196 0.822
CT
TT
TC CC 0.214 0.808
CT
TT
HDL-C CC 0.173 0.841
CT
TT
LDL-C CC 0.304 0.738
CT
TT
BMI = Body mass index; SBP = Systolic blood pressure;
DBP= Diastolic blood pressure; MBP=Mean blood pressure;
CIMT= Carotid intima media thickness; FSG= Fasting serum
glucose; CRP = C-reactive protein; TG= Triglycerides;
TC = Total cholesterol; HDL-C = High density lipoprotein frac-
tions.LDL-C = Low density lipoprotein fractions.
P< 0.05 is signiﬁcant.
272 M.H. Kandil et al.genotype distribution of IL-1B polymorphisms between a sin-
gle vessel disease atherosclerosis group and the control group
or multiple vessel disease group and controls or coronary ar-
tery disease and the control groups in the Turkish population.
He concluded that those polymorphisms may modulate some
of processes for the development of CAD. Zee et al. [25], in
their study on seven gene polymorphisms within the interleu-kin-1 gene cluster among American men who subsequently
developed athero-thrombotic events found that IL-1B -511C/
T polymorphism was not associated with risk of athero-throm-
botic disorders, and after further adjustment for traditional
cardiovascular risk factors they yielded similar null ﬁndings.
The current work was also consistent with previous ﬁndings
of Li et al. [26] who concluded the same results in Chinese pop-
ulation. In addition, Ye et al. [27] in their meta-analysis which
enhances the statistical power and draws a more reliable con-
clusion compared to a single study indicated that there was no
association between IL-1B -511C/T polymorphism and athero-
sclerosis and ischaemic stroke risk. Interestingly, when sub-
group analyses for countries were performed, the results
indicated that T allele was associated with increased risk of
atherosclerosis and ischaemic stroke for Polish and associated
with a trend of increased risk in Chinese population so they
concluded the same results but inferred that IL-1B -511C/T
polymorphism might be moderately associated with increased
risk of atherosclerosis and ischaemic stroke [28]. In contrast,
the data presented by Iacoviello et al. [29] indicated that the
IL-1B (-511C/C) genotype was associated with myocardial
infarction and ischaemic stroke at young age and increased
the response of mononuclear cells to inﬂammatory stimula-
tion. Also Soylu et al. [30] found that IL-1B allele C (-511)
polymorphism in unstable angina pectoris patients was signif-
icantly different from that of control subjects in the Turkish
population. In another controversial study, Zhang et al. [31]
found that the distribution of IL-1B -511C/T polymorphism
between ACS in the Chinese patients and controls was signif-
icantly different and CT and TT genotype carriers were at
increasing risk of ACS with more than double ratio to CC
genotype. He concluded that the polymorphism at position -
511C/T in IL-1B is associated with the severity of coronary
heart disease (CHD), and the DNA variation at this position
may affect the secretion of IL-1B, and aggravate the reaction
of inﬂammation and dyslipidemia. Also Oda et al. [24] found
that -511T of IL-1beta was a signiﬁcant risk factor for
atherogenesis in the subclavian and intracranial arteries. In
contrast, conventional risk factors for atherogenesis, such as
hypertension and diabetes mellitus, conferred independent
risks for almost all arteries. He concluded that functional
SNPs in IL-1beta gene may play a role in atherogenesis,
although their inﬂuences are less pronounced than those of
conventional risk factors and appear to be limited to speciﬁc
arteries in the elderly Japanese.
In the present study, no signiﬁcant relation was found be-
tween IL-1B (-511C > T) variants and the different studied
parameters. Another study in patients with end stage renal dis-
ease reported that males carrying IL-1B (-511T/T) showed a
higher body mass index [32]. In addition, patients with hyper-
tensive CHD carrying IL-1B -511C/T or T/T showed reduced
CRP levels compared to those carrying IL-1B -511C/C [33].
Atherosclerosis is a multifactorial process determined by
several genes, environmental factors and their interaction. It
is characterized by chronic inﬂammation on the inner layer
of the arterial wall, and several cytokines are related to the
arterial wall inﬂammatory process [34]. It has been shown that
IL-6 has strong predictivity on cardiovascular mortality than
CRP in haemodialysis patients [35,36], and that IL-6 (G-
174C) gene polymorphism modiﬁes IL-6 production in non-re-
nal and in renal patients [37,38].
Table 6 Genotype frequencies of IL-6 -174(G > C) polymorphism among the studied groups.
Genotype n Control group (n= 30) Group A (n= 33) Group B (n= 37) Total patients (n= 70)
%
GG n 21 23 31 54
% 70.0 69.7 83.8 77.1
GC n 8 9 5 14
% 26.7 27.3 13.5 20
CC n 1 1 1 2
% 3.3 3.0 2.7 2.9
Chi-square p-value 2.689
0.611
Group A: Patients with ESRD on maintenance haemodialysis without atherosclerosis.
Group B: Patients with ESRD on maintenance haemodialysis with atherosclerosis.
n: Number of subjects.
P< 0.05 is signiﬁcant.
Table 7 IL-6 -174(G > C) allele frequency among the studied groups.
Allele n Control group (n= 30) Group A (n= 33) Group B (n= 37) Total patients (n= 70)
%
G n 50 55 67 122
% 83.3 83.3 90.5 87.1
C n 10 11 7 18
% 16.7 16.7 9.5 12.9
Chi-square p-value 2.01
0.365
Group A: Patients with ESRD on maintenance haemodialysis without atherosclerosis.
Group B: Patients with ESRD on maintenance haemodialysis with atherosclerosis.
n: Number of subjects.
P< 0.05 is signiﬁcant.
Possible association of interleukin-1beta (-511C/T) and interleukin-6 (-174G/C) 273In the present study, the genotype distribution and allele
frequency for IL-6 (-174G/C) were compared in all subjects.
No signiﬁcant difference was observed in the genotype distri-
bution of IL-6 (-174G/C) among the studied groups. In addi-
tion, no signiﬁcant difference was observed in the frequency
of the IL-6 (-174) alleles among the studied groups. Also, no
signiﬁcant relation was found between IL-6 (-174G/C) variants
and the different studied parameters. These results were in
agreement with Sekuri et al. [39] who found that IL-6 -
174G/C polymorphism is not associated with the risk of pre-
mature CAD, and does not contribute to cardiovascular risk
stratiﬁcation in the Turkish population. Jang et al. [40] found
no association between IL-6 -174G/C polymorphism and ath-
erosclerosis in Korean men, and Banerjee et al. [41] found the
same results in Indian population. Also Lo´pez-Mejı´as et al.
[42] conﬁrmed the lack of association between IL-6 -174G/C
gene polymorphism and CVD in Spanish patients. Our results
were also comparable to those reported by Ghazouani et al.
[43] who found that the distribution of -174G > C genotypes
was similar between CAD patients and control subjects in
Tunisians. Moreover, compared to GG genotype carriers, -
174C allele carriage did not increase the CAD relative risk,
which remained non signiﬁcant after adjusting for traditional
risk factors for CAD (age, smoking, hypertension, diabetes
and obesity). In addition, Ye et al. [25] did not ﬁnd any sufﬁ-
cient evidence to support an association between IL-6 -147G/C
polymorphism and atherosclerosis.The Northwick Park Heart Study, a prospective study of
middle-aged healthy men, reported that the risk imparted by
the -174G/C genotype was higher than that imparted by the
-174C/C genotype, also they demonstrated a weak but signiﬁ-
cant association of the -174G > C variant with increased ath-
erosclerosis risk and these effects remained statistically
signiﬁcant after adjusting for classical risk factors including
blood pressure [44]. A Greek study demonstrated enrichment
of the -174C allele in patients with myocardial infarction sug-
gesting that the -174G/C variant may be involved in the path-
ogenesis of atherosclerosis [45]. Also Berg et al. [46] found that
individuals who were homozygous for the C-allele had a higher
risk for atherosclerosis both in univariate and multivariate
analyses in Norwegian population.
Given the well-established role of inﬂammatory mecha-
nisms in atherosclerosis pathogenesis, coupled with the role
of IL-6 as a pro-inﬂammatory cytokine, it is tempting to spec-
ulate that induction of inﬂammation mediated by altered IL-
1B and IL-6 levels regulated by speciﬁc IL-1B and IL-6 gene
variants may modulate atherosclerosis development and pro-
gression especially in dialysis condition. However from the
ﬁndings of the present work, it could be concluded that IL-
1B (-511C/T) and IL-6 (-174G/C) genetic variations are unli-
kely to play an important role in the genetic predisposition
to atherosclerosis. Conﬂicting results may be due to various
reasons such as demographic features of subjects and different
life styles; also sample size plays a crucial role. This situation
Table 8 Comparison of the measured variables between
different genotypes of IL-6 -174(G > C) polymorphism.
Variables Genotypes F Sig.
Weight GG 0.264 0.769
GC
CC
Height GG 0.972 0.382
GC
CC
BMI GG 1.467 0.236
GC
CC
SBP GG 0.085 0.919
GC
CC
DBP GG 1.154 0.320
GC
CC
MBP GG 0.515 0.599
GC
CC
CIMT GG 0.773 0.465
GC
CC
FSG GG 0.171 0.843
GC
CC
Creatinine GG 0.188 0.829
GC
CC
Albumin GG 0.218 0.804
GC
CC
CRP GG 1.897 0.155
GC
CC
TG GG 1.656 0.196
GC
CC
TC GG 1.957 0.147
GC
CC
HDL-C GG 0.672 0.513
GC
CC
LDL-C GG 2.074 0.131
GC
CC
BMI = Body mass index; SBP = Systolic blood pressure;
DBP= Diastolic blood pressure; MBP=Mean blood pressure;
CIMT= Carotid intima media thickness; FSG= Fasting serum
glucose; CRP = C-reactive protein; TG= Triglycerides;
TC = Total cholesterol; HDL-C = High density lipoprotein frac-
tions; LDL-C = Low density lipoprotein fractions.
P< 0.05 is signiﬁcant.
274 M.H. Kandil et al.encourages more and more attempts to be made to further as-
sess the associations of these polymorphisms with the disease.
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